|
|
 |
|
Viewing report
|
|
|
|
Chronic Leukemias - Curative Intent Raises The Bar
Datamonitor, Oct 2005, Pages: 174
Introduction
Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovative treatments to cohorts most likely to respond, developers should increasingly employ the use of molecular markers to guide risk stratification.
Scope
- Overview of chronic leukemias including epidemiology, etiology, clinical features, staging and prognostic variables
- Current treatment controversies and novel therapies in the developmental pipeline
- Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development
- Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe
Highlights
Because of the heterogeneity of CLL there is a need to identify biological markers that provide a more robust and reliable prediction of patient outcomes to current and evolving treatment strategies. The identification and application of molecular markers to facilitate prognostication is becoming integral to the treatment decision-making process.
The emergence of Gleevec-resistant CML, reported at rates of 4% with each year of treatment, coupled with only a 50% response rate in patients with advanced disease, indicate the need for novel, efficacious second-line treatment strategies both for patients with Gleevec-resistant chronic phase CML and for virtually all advanced stage patients.
The goal for developers of novel CLL pharmacotherapy is to innovate drug treatments that can salvage patients refractory to alemtuzumab and improve on the formers toxicity while simultaneously increasing the rate and duration of minimal residual disease negativity.
Reasons to Purchase
- Identify opportunities for more efficacious second-line treatment strategies both for patients with Gleevec-resistant CML and advanced stage patients
- Understand how future advancements in chronic leukemia prognostication have the potential to shift treatment paradigms
- Assess opportunities and challenges facing innovative treatments for chronic leukemias, in particular the drive to eradicate minimal residual disease
Customers who bought this item also bought
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Stakeholder Insight: Chronic Leukemias - Is there Room left for Improvement?
Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use
Autoimmune Disease Series: Systemic Sclerosis--Novel Treatment Approaches on the Horizon
Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
Treatment Algorithms 2002: Heart failure - managing chronic and acute patients
Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Drugs of Tomorrow: Leukemia - Chemopotentiators Will Drive Growth in the Acute Leukemia Markets
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia
|
|
|
|
